faz.net
🌐 85% Global Worthiness
Novartis Reports Record 2024 Sales Despite Morphosys Write-Down
Novartis announced record 2024 financial results: \$50.3 billion in sales (up 11%), \$19.5 billion in operating core earnings (up 19%), and \$11.9 billion in net income (up 39%), driven by innovative medicines; however, a \$900 million write-down from the Morphosys acquisition impacted the results.
Novartis Reports Record 2024 Sales Despite Morphosys Write-Down
Novartis announced record 2024 financial results: \$50.3 billion in sales (up 11%), \$19.5 billion in operating core earnings (up 19%), and \$11.9 billion in net income (up 39%), driven by innovative medicines; however, a \$900 million write-down from the Morphosys acquisition impacted the results.
Progress
44% Bias Score
Good Health and Well-being